{
  "paper_metadata": {
    "pmid": "31117178",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on TTR variants, including penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.89G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 172,
        "demographics": "adults with hereditary TTR amyloidosis",
        "phenotype": "polyneuropathy"
      },
      "penetrance_data": {
        "total_carriers_observed": 172,
        "affected_count": 112,
        "unaffected_count": 60,
        "uncertain_count": null,
        "penetrance_percentage": 65.12,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "polyneuropathy",
          "evidence_sentence": "A phase 3 trial (NCT01737398) of Tegsedi in adults with stage 1 or stage 2 hereditary TTR amyloidosis with polyneuropathy was run with a total of 172 patients (112 in the Tegsedi group and 60 in the placebo group), nearly half of them carrying the Val30Met mutation."
        }
      ],
      "functional_data": {
        "summary": "The Val30Met mutation leads to destabilization of TTR, contributing to amyloid fibril formation.",
        "assays": [
          "clinical trial assessments",
          "neuropathy impairment score",
          "quality of life assessments"
        ]
      },
      "segregation_data": "The Val30Met variant is known to segregate with disease in families.",
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study included a significant number of patients with the Val30Met mutation, indicating its relevance in hereditary TTR amyloidosis.",
      "key_quotes": [
        "nearly half of them carrying the Val30Met mutation.",
        "Results revealed that Tegsedi slowed the progression of nerve cell damage and improved the quality of life of the patients."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data regarding the TTR variant was extracted from the main text."
  }
}